Peter Ho, MD, PhD, has focused on cancer drug discovery and development since completing his medical training at the Dana-Farber Cancer Institute. He served as a Staff Fellow at the U.S. Food and Drug Administration and then as a Senior Investigator at the Investigational Drug Branch of the Cancer Therapy Evaluation Program of the National Cancer Institute. His pharmaceutical experience has included positions of increasing responsibility at Novartis Pharmaceuticals, DuPont Pharmaceuticals, GlaxoSmithKline, and Johnson and Johnson. Since 1995, he has been responsible for the first-time-in-human dosing of 17 anticancer agents and has overseen the development of over 50 oncology compounds in clinical phases of testing. These compounds have included small molecule inhibitors of intracellular signal transduction cascades, direct cytotoxic agents, hormonal antagonists, epigenetic modulators, radiopharmaceuticals, cytokines, monoclonal antibodies, monoclonal antibody conjugates and oncology supportive care agents. This work has contributed to five NCE approvals to date: Gleevec, Arranon, Tykerb, Promacta and Votrient. He currently is the Chief Medical Officer at Epizyme.